{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-408224","form_type":"8-K","ticker":"SGMT","cik":"0001400118","company_name":"Sagimet Biosciences Inc.","filed_at":"2026-09-30T10:09:56+00:00","discovered_at":"2026-09-30T10:15:00.722616+00:00","generated_at":"2026-10-12T13:55:46.490044+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Sagimet: denifanstat hits 56.7% IGA success at 52 weeks in Ascletis Phase 3 OLE; US AURORA screening starts October","bullets":["52-week Phase 3 OLE (ASC40-304) in China: 56.7% treatment success across 240 patients (57.8% denifanstat/denifanstat vs 55.6% placebo/denifanstat).","Mean reductions vs ASC40-303 baseline: total lesion count -71.8%, inflammatory lesions -76.9%, non-inflammatory lesions -66.9%.","Denifanstat 50 mg was generally well-tolerated up to 52 weeks: no permanent discontinuations or drug-related serious AEs; dry skin 7.1%, dry eye 5.9%.","Sagimet's US AURORA Phase 3 screening begins October 2026: ~800 patients (450 aged 12-17), randomized 2:1 to denifanstat 50 mg or placebo over 12 weeks.","Sagimet terminated the ATM prospectus supplement under its Aug 14, 2025 Sales Agreement with Leerink Partners; no further share sales unless a new prospectus is filed."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-408224","json":"https://secwatch.observer/filing/0001193125-26-408224.json","markdown":"https://secwatch.observer/filing/0001193125-26-408224.md","text":"https://secwatch.observer/filing/0001193125-26-408224.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1400118/000119312526408224/0001193125-26-408224-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1400118/000119312526408224/d96035d8k.htm"},"model":{"generated_by":"deepseek-v4.1-flash:cloud@v2","generated_at":"2026-10-12T13:55:46.490044+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}